Intra-Arterial thrombolysis after SUCCESSful angiographic recanalization in acute large-vessel occlusion stroke of the anterior circulation (IA-SUCCESS): a multicentre, randomised, clinical trial protocol.
Benjamin Gory, Sébastien Richard, Raoul Pop, Valérie Wolff, Aboubaker Cherifi, Martin Bretzner, Hilde Henon, Gaultier Marnat, Igor Sibon, Jean-Christophe Gentric, Serge Timsit, Fortunato Di Caterino, Guillaume Charbonnier, Jildaz Caroff, Christian Denier, Arturo Consoli, Bertrand Lapergue, Julien Allard, Gaspard Gerschenfeld, Victor Dumas, Matthias Lamy, Sebastian Johan Richter, Hélène Castagnet, Louis Veunac, Quentin Bourgeois-Beauvais, Jean-Philippe Desilles, Pierre Seners, Olivier Naggara, Anne-Christine Januel, Louis Fontaine, Grégoire Boulouis, Marco Pasi, Cyril Dargazanli, Caroline Arquizan, Olivier Heck, Katia Garambois, Pierre-Olivier Comby, Yannick Bejot, François Zhu, Liang Liao, Wassim Abou Loukoul, Anne-Laure Derelle, René Anxionnat, Marius Mkounga Kamga, Hamza Hachit, Francis Guillemin, Guillaume Turc, Gabriela Hossu
Eur Stroke J 11(7) aakag080
摘要
摘要
BACKGROUND: Intra-arterial thrombolysis (IAT) following successful mechanical thrombectomy (MT) in patients with anterior circulation large-vessel occlusion (LVO) improves cerebral tissue reperfusion and consequently clinical outcome, but has to be validated in non-Asian populations. We hypothesised that IAT with alteplase versus no IAT leads to a better clinical outcome in patients with anterior circulation LVO stroke who have successful angiographic recanalisation. STUDY DESIGN: Intra-Arterial thrombolysis after SUCCESSful angiographic recanalization in acute large-vessel occlusion stroke of the anterior circulation (IA-SUCCESS) trial is a phase 3 investigator-initiated, multicentre, randomised, open-label, blinded-endpoint (PROBE) clinical trial with a health economic evaluation conducted in France. Patients with acute ischaemic stroke due to anterior circulation LVO within 24 h of stroke onset and successful angiographic reperfusion (defined as extended Thrombolysis in Cerebral Infarction score 2b-3) after intravenous thrombolysis alone, MT alone or both will be randomised in two balanced parallel groups (1:1) to receive either IAT with alteplase (0.225 mg kg-1 and a maximum of 20 mg) injected in the ipsilateral internal carotid artery or no IAT. A total of 626 patients will be included. STUDY ENDPOINTS: The primary outcome is the functional outcome on the modified Rankin Scale at 90 (±15) days. Standard secondary clinical outcomes are assessed at 24 (±6) h, 5-7 days, 90 (±15) days and 12 (±1) months. Safety outcomes include mortality at 90 (±15) days and intracranial haemorrhage. SUMMARY: The IA-SUCCESS trial will provide high-quality randomised data on the clinical efficacy and safety of intra-arterial alteplase following successful angiographic recanalisation in European patients with ischaemic stroke due to anterior circulation LVO intended for MT. TRIAL REGISTRATION: ClinicalTrials.gov NCT06768138.
KM 提取结果
0 个 Figure · 0 个 KM 面板